Boehringer Mannheim Gmbh

Hoffmann-la Roche Inc.

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Albert-ludwigs-universitat Freiburg

F. Hoffmann-la Roche Ag

Michael Jarsch

Christoph Kessler

Klaus Kaluza

Olaf Mundigl

Bruno Frey

Gudrun Schmitz-Agheguian

Gudrun Schmitz

Gunter Lang

Erhard Kopetzki

Rainer Rudolph

Manfred Kubbies

Frank Herting

Bryan J Bolton

Helmut Burtscher

Uwe Michaelis

August Bock

Max Lechner

Anton Haselbeck

Jens Timmer

Agustin Rodriguez Gonzalez

Max Schelker

Marcel Schilling

Bernhard Steiert

Barbara Prinz

Ursula Klingmueller

Hans J Hoeltke

Gether Schumacher

Roland Herbst

Andreas Raue

Nora Torres-Nagel

Robert Gary Sawers

Ursula Klingmüller

Joerg Huwyler

An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Methods for the prediction of a personalized ESA-dose in the treatment of anemia

An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor.

Antibodies against human EPO receptor

Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

Anti-human EPO receptor antibodies and methods of use

Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies

Cholesterol oxidase from Brevibacterium sterolicum

The recombinant DNA according to the present invention contains a regulator region which is different from the pfl gene; a promoter region upstream from the gene which contains a -35/-10 promoter sequence; a regulator region upstream from the promoter region which contains a sequence (I) 5'-GAGATATGATCTATATCAATTTC-3' or a 23 base pair sequence which is at least 80% identical to positions 6-10 and 15-19 of said sequence (I) but not having C at position 8 and/or G at position 17. An expression vector according to the present invention contains a recombinant DNA according to the present invention ligated into a suitable vector molecule and methods are also described for expression the DNA.

Recombinant DNA and expression vector for the repressible and inducible

In a process for the production of recombinant, biologically active, eukaryotic alkaline phosphatase a DNA sequence coding for a eukaryotic alkaline phosphatase is expressed in a prokaryotic host cell and the expression product is obtained in an active form by cell lysis, solubilization under denaturing conditions and subsequent renaturation. In this process the renaturation step is carried out in the presence of one or several stabilizing agents.

Process for the production and renaturation of recombinant, biologically

The invention concerns a glucose-6-phosphate dehydrogenase which contains the amino acid sequence shown in SEQ ID NO:1 as well as a DNA coding for it and a process for the isolation of an enzyme according to the present invention.

Cloning and overexpression of glucose-6-phosphate dehydrogenase from

The new type II restriction endonuclease Ssp4800I has the following recognition sequence: ##STR1## and preferably cleaves at the cleavage site defined by the arrows. It is preferably obtainable from microorganisms of the genus Streptomyces.

Type II restriction endonuclease Ssp4800I

The novel type II restriction endonuclease SwaI has the following recognition sequence: ##STR1## and preferably cleaves at the cleavage site indicated by the line. It is preferably obtainable from microorganisms of the genus Staphylococcus.

Type II restriction endonuclease SwaI

Type II restriction endonuclease MamI

Type II restriction endonuclease McrI is disclosed. This endonuclease has recognition sequence: ##STR1## wherein R is G or A and Y is C or T, and the cleavage site indicated by the arrows. The endonuclease is preferably obtained from organism of genus Micrococcus. It can be used to recognize and cleave double stranded DNA sequence:

Type II restriction endonucleae MCRI

The type II restriction endonuclease RleAI has the following recognition sequence: ##STR1## cleaves DNA at the cleavage site indicated by the arrows, and is preferably obtainable from microorganisms of the genus Rhizobium. It can be used to recognize and cleave the double-stranded DNA sequence CCCACA(N).sub.12/9 and its complementary sequence.

Type II restriction endonuclease RleAI

The type III restriction endonuclease SgrAI has the following recognition sequence: ##STR1## cleaves DNA at the cleavage site indicated by the arrows, and is preferably obtainable from microorganisms of the genus Streptomyces. It can be used to recognize and cleave the double-stranded DNA sequence ##STR2## and its complementary sequence.

Type II restriction endonuclease SgrAI

Growing community of inventors

Bad Heilbrunn, Germany

Michael Jarsch